Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 272

1.

Assessment of Frequency and Reporting of Changes in Cancer Trial Design After Initiation of Patient Accrual.

Shepshelovich D, Tibau A, Molto C, Goldvaser H, Ocana A, Šeruga B, Amir E.

JAMA Oncol. 2018 Dec 6. doi: 10.1001/jamaoncol.2018.5877. [Epub ahead of print] No abstract available.

PMID:
30520936
2.

A prospective intervention to improve happiness and reduce burnout in oncologists.

Clemons M, Mazzarello S, Pond G, Amir E, Asmis T, Berry S, Brackstone M, Brule S, Goodwin R, Hilton JF, Julião M, Nicholas G, Stewart DJ, Wheatley-Price P, Cholmsky L, Krentel A, Hutton B, Joy AA.

Support Care Cancer. 2018 Nov 30. doi: 10.1007/s00520-018-4567-5. [Epub ahead of print]

PMID:
30506102
3.

Competing risks of extended adjuvant aromatase inhibitors.

Amir E.

Lancet Oncol. 2018 Nov 30. pii: S1470-2045(18)30663-6. doi: 10.1016/S1470-2045(18)30663-6. [Epub ahead of print] No abstract available.

PMID:
30509770
4.

Acute Kidney Injury in Patients Receiving Systemic Treatment for Cancer: A Population-Based Cohort Study.

Kitchlu A, McArthur E, Amir E, Booth CM, Sutradhar R, Majeed H, Nash DM, Silver SA, Garg AX, Chan CT, Kim SJ, Wald R.

J Natl Cancer Inst. 2018 Nov 13. doi: 10.1093/jnci/djy167. [Epub ahead of print]

PMID:
30423160
5.

Sorafenib as first-line therapy in patients with advanced Child-Pugh B hepatocellular carcinoma-a meta-analysis.

McNamara MG, Slagter AE, Nuttall C, Frizziero M, Pihlak R, Lamarca A, Tariq N, Valle JW, Hubner RA, Knox JJ, Amir E.

Eur J Cancer. 2018 Dec;105:1-9. doi: 10.1016/j.ejca.2018.09.031. Epub 2018 Oct 29.

PMID:
30384012
6.

Absolute benefit from adjuvant chemotherapy in contemporary clinical trials: A systemic review and meta-analysis.

Goldvaser H, Ribnikar D, Majeed H, Ocaña A, Amir E.

Cancer Treat Rev. 2018 Dec;71:68-75. doi: 10.1016/j.ctrv.2018.10.010. Epub 2018 Oct 17. Review.

PMID:
30366201
7.

Cardiac Outcomes in Pregnant Women With Treated Cancer.

Liu S, Aghel N, Belford L, Silversides CK, Nolan M, Amir E, Maxwell C, Thavendiranathan P.

J Am Coll Cardiol. 2018 Oct 23;72(17):2087-2089. doi: 10.1016/j.jacc.2018.07.085. No abstract available.

PMID:
30336834
8.

Refining Early Antitumoral Drug Development.

Ocaña A, García-Alonso S, Amir E, Pandiella A.

Trends Pharmacol Sci. 2018 Nov;39(11):922-925. doi: 10.1016/j.tips.2018.09.003. Epub 2018 Sep 29.

PMID:
30279003
9.

Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration Based on Single-Arm Trials.

Tibau A, Molto C, Borrell M, Del Paggio JC, Barnadas A, Booth CM, Amir E.

JAMA Oncol. 2018 Nov 1;4(11):1610-1611. doi: 10.1001/jamaoncol.2018.4300. No abstract available.

PMID:
30267037
10.

Epigenetic modulation of FOXM1-gene interacting network by BET inhibitors in breast cancer.

Pérez-Peña J, Győrffy B, Amir E, Pandiella A, Ocaña A.

Breast Cancer Res Treat. 2018 Sep 11. doi: 10.1007/s10549-018-4965-x. [Epub ahead of print]

PMID:
30206781
11.

Evolution in sites of recurrence over time in breast cancer patients treated with adjuvant endocrine therapy.

Algorashi I, Goldvaser H, Ribnikar D, Cescon DW, Amir E.

Cancer Treat Rev. 2018 Nov;70:138-143. doi: 10.1016/j.ctrv.2018.08.009. Epub 2018 Aug 24. Review.

PMID:
30176513
12.

Dual targeting of HER2-positive breast cancer with trastuzumab emtansine and pertuzumab: understanding clinical trial results.

Ocaña A, Amir E, Pandiella A.

Oncotarget. 2018 Aug 7;9(61):31915-31919. doi: 10.18632/oncotarget.25739. eCollection 2018 Aug 7. Review.

13.

Expedited approval of cancer drugs without randomized controlled trials: Too good to be true?

Shepshelovich D, Amir E.

Oncotarget. 2018 Jul 24;9(57):30942-30943. doi: 10.18632/oncotarget.25799. eCollection 2018 Jul 24. No abstract available.

14.

Unmet needs of family caregivers of hospitalized older adults preparing for discharge home.

McCusker J, Yaffe M, Lambert SD, Cole M, de Raad M, Belzile E, Ciampi A, Amir E, Hidalgo M.

Chronic Illn. 2018 Aug 4:1742395318789467. doi: 10.1177/1742395318789467. [Epub ahead of print]

PMID:
30079741
15.

Health status, emergency department visits, and oncologists' feedback: An analysis of secondary endpoints from a randomized phase II geriatric assessment trial.

Sattar S, Alibhai SMH, Brennenstuhl S, Kulik M, MacDonald ME, McWatters K, Lee K, Jang R, Amir E, Krzyzanowska MK, Joshua AM, Monette J, Wan-Chow-Wah D, Puts MTE.

J Geriatr Oncol. 2018 Jul 21. pii: S1879-4068(18)30159-0. doi: 10.1016/j.jgo.2018.06.014. [Epub ahead of print]

PMID:
30041978
16.

Association of Metabolic, Inflammatory, and Tumor Markers With Circulating Tumor Cells in Metastatic Breast Cancer.

Lohmann AE, Dowling RJO, Ennis M, Amir E, Elser C, Brezden-Masley C, Vandenberg T, Lee E, Fazaee K, Stambolic V, Goodwin PJ, Chang MC.

JNCI Cancer Spectr. 2018 Apr;2(2):pky028. doi: 10.1093/jncics/pky028. Epub 2018 Jul 12.

17.

Catalytic Functionalization of C-H Bonds of Azulene by Carbene/Nitrene Incorporation.

Carreras J, Popowski Y, Caballero A, Amir E, Pérez PJ.

J Org Chem. 2018 Sep 21;83(18):11125-11132. doi: 10.1021/acs.joc.8b01731. Epub 2018 Jul 26.

PMID:
30032616
18.

Importance of Considering Competing Risks in Time-to-Event Analyses: Application to Stroke Risk in a Retrospective Cohort Study of Elderly Patients With Atrial Fibrillation.

Abdel-Qadir H, Fang J, Lee DS, Tu JV, Amir E, Austin PC, Anderson GM.

Circ Cardiovasc Qual Outcomes. 2018 Jul;11(7):e004580. doi: 10.1161/CIRCOUTCOMES.118.004580.

PMID:
29997149
19.

Representation of Patients With Chronic Kidney Disease in Trials of Cancer Therapy.

Kitchlu A, Shapiro J, Amir E, Garg AX, Kim SJ, Wald R, Harel Z.

JAMA. 2018 Jun 19;319(23):2437-2439. doi: 10.1001/jama.2018.7260. No abstract available.

PMID:
29922818
20.

Personalized medicine in immuno-oncology: a novel prognostic index in non-small cell lung cancer.

Majeed H, Amir E.

J Thorac Dis. 2018 Apr;10(Suppl 9):S995-S998. doi: 10.21037/jtd.2018.03.153. No abstract available.

Supplemental Content

Loading ...
Support Center